CSL Limited (CSLLY) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Melbourne, VIC, オーストラリア. 現CEOは Gordon Naylor DipCompSc.
CSLLY を有する IPO日 2009-12-29, 32,698 名の正社員, に上場 Other OTC, 時価総額 $95.92B.
CSL Limited is a global biopharmaceutical company headquartered in Parkville, Australia, with operations across the United States, Europe, China, and other international markets. The company operates through two primary divisions: CSL Behring, which specializes in plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, and neurological conditions, and Seqirus, which focuses on non-plasma biotherapeutics and influenza-related products. CSL Limited researches, develops, manufactures, and distributes a comprehensive portfolio of biopharmaceutical products while also generating revenue through licensing and royalty agreements. Founded in 1916, the company has established itself as a leader in the biopharmaceutical industry through its innovative therapeutic solutions and global market presence.